NeurologyLive

10/20/2025

Leading multiple sclerosis (MS) experts Enrique Alvarez, MD, PhD, and Stephen Krieger, MD, FAAN, explore how anti-CD20 therapies are shaping the landscape of relapsing MS treatment—delving into their efficacy, safety, and real-world outcomes over the long term. The discussion also highlights key considerations for therapy de-escalation, switching strategies, and the importance of aligning treatment decisions with patient goals and evolving clinical evidence.

Discover how emerging approaches are redefining what’s possible in MS care.

Watch Now: https://hubs.li/Q03PnsDW0

10/19/2025

: Our latest Mind Moments podcast episode features a conversation with Orrin Devinsky, MD, of NYU Grossman School of Medicine, as he discusses major areas of progress and ongoing challenges in care.

Listen Now:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Orrin Devinsky, MD. [LISTEN TIME: 24 minutes]

10/19/2025

Data from the phase 2 ELATE trial showed that onabotulinumtoxinA met the primary end point of reducing tremor-related disability compared with placebo in patients with upper limb essential tremor over 18 weeks. International Parkinson and Movement Disorder Society AbbVie

View more:

A phase 2 study presented at MDS 2025 revealed that onabotulinumtoxinA significantly improved tremor-related disability compared with placebo in patients with upper limb essential tremor.

10/19/2025

Data from a phase 3 trial of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy demonstrated significant improvements in motor function among patients with disease experiencing motor complications. International Parkinson and Movement Disorder Society

Read More:

A phase 3 trial presented at MDS 2025 suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

10/18/2025

New phase 3 data presented by Brenda Banwell, MD, support ocrelizumab for pediatric relapsing MS. But Banwell warns that pediatric trials still lag a decade behind adult MS studies due to recruitment, trial design, and regulatory barriers. Here’s what she says needs to change.

View:

The pediatrician in chief at Johns Hopkins Children’s Center outlined the logistical, ethical, and regulatory hurdles of conducting pediatric MS trials, emphasizing the need for faster, more inclusive study designs to bring emerging therapies to clinic. [WATCH TIME: 5 minutes]

10/18/2025

Gavin Giovannoni, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeutic benefit in more advanced forms of multiple sclerosis.

Read more:

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeutic benefit in more advanced forms of multiple sclerosis.

10/18/2025

In a new Q&A✍️, Guilherme Dabus, MD, co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.

The co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.

10/18/2025

Anne O’Donnell-Luria, MD, PhD, a practicing clinical geneticist at Boston Children’s Hospital, sat down at CNS 2025 to discuss advances in genomic diagnostics, variant interpretation, and the expanding impact of neurogenetic discovery on clinical practice.

Read here:

Anne O’Donnell-Luria, MD, PhD, a practicing clinical geneticist at Boston Children’s Hospital, sat down at CNS 2025 to discuss advances in genomic diagnostics, variant interpretation, and the expanding impact of neurogenetic discovery on clinical practice.

10/18/2025

🎧 New Mind Moments episode just dropped! NYU’s Orrin Devinsky, MD, discusses how epilepsy care is evolving — from treatment strategies and gene therapy to neurodevelopmental care.

Listen in: https://hubs.li/Q03Pcq-c0

10/18/2025

🚶🧠 Data from a phase 2 trial, presented at the 2025 , showed that once daily administration of VTX3232, an investigational oral NLRP3 inhibitor, was safe and associated with improvement in both motor and nonmotor symptoms in patients with early-stage disease. International Parkinson and Movement Disorder Society

📈See the results now:

In phase 2a trial presented at MDS 2025, findings showed that VTX3232 achieved drug levels in plasma and cerebrospinal fluid that exceed the IC90 for NLRP3 inhibition by more than 3-fold.

10/17/2025

🚼 🧠 At the 2025 , a poster presented the design and rationale for OPAL, a 52-week phase 2 trial of investigational apitegromab in infants with spinal muscular atrophy (SMA) under 2 years old who have already received gene therapy or are currently treated with nusinersen or risdiplam. Child Neurology Society

👀 View the study design here:

Apitegromab, an invesigational muscle-targeting treatment, showed promising results in improving motor function among young patients with SMA in a phase 2 trial.

10/17/2025

🔬📝 Data from cohort A of the ROSSINI study indicated that use of foslevodopa/foscarbidopa led to sustained improvements in motor and nonmotor symptoms among patients with advanced disease after 6 months of treatment. AbbVie International Parkinson and Movement Disorder Society 🧠💊

Details here:

New real-world data presented at MDS 2025 demonstrated that foslevodopa/foscarbidopa reduced motor fluctuations and improved quality of life in patients with advanced Parkinson disease over 6 months.